BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30715659)

  • 1. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
    Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
    Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
    Prathibha S; White M; Kolbow M; Hui JYC; Brauer D; Ankeny J; Jensen EH; LaRocca CJ; Marmor S; Tuttle TM
    Breast Cancer Res Treat; 2024 May; 205(1):127-133. PubMed ID: 38281296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
    Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
    Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
    Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
    Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
    Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
    Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
    Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.
    Morrow M; Van Zee KJ; Patil S; Petruolo O; Mamtani A; Barrio AV; Capko D; El-Tamer M; Gemignani ML; Heerdt AS; Kirstein L; Pilewskie M; Plitas G; Sacchini VS; Sclafani LM; Ho A; Cody HS
    Ann Surg; 2017 Sep; 266(3):457-462. PubMed ID: 28650355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
    Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A
    Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population.
    Yi M; Kuerer HM; Mittendorf EA; Hwang RF; Caudle AS; Bedrosian I; Meric-Bernstam F; Wagner JL; Hunt KK
    J Am Coll Surg; 2013 Jan; 216(1):105-13. PubMed ID: 23122536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
    Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
    JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study.
    Delpech Y; Bricou A; Lousquy R; Hudry D; Jankowski C; Willecocq C; Thoury A; Loustalot C; Coutant C; Barranger E
    Ann Surg Oncol; 2013 Aug; 20(8):2556-61. PubMed ID: 23456432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axillary management based on American college of surgeons oncology group Z0011 criteria makes it possible to omit intraoperative diagnosis of sentinel lymph nodes in early breast cancer patients.
    Kittaka N; Nakajima S; Hatano T; Seto Y; Kusama H; Matsui S; Nishio M; Fujisawa F; Honma K; Nakayama T; Tamaki Y
    Breast J; 2021 Nov; 27(11):804-810. PubMed ID: 34558164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
    Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
    Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria].
    Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E
    Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing single or dual tracing modality on sentinel lymph node biopsy from patients who plan to omitting axillary lymph node dissection referring to the criteria of Z0011 trial: a retrospective study.
    Xu Y; Wu H; Zhang W; Shen Y; Jiang Y; Meng L
    Updates Surg; 2022 Jun; 74(3):1073-1078. PubMed ID: 35389176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do the ACOSOG Z0011 Criteria Affect the Number of Sentinel Lymph Nodes Removed?
    Subhedar P; Stempel M; Eaton A; Morrow M; Gemignani ML
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(0 3):S470-5. PubMed ID: 26178759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
    Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is SLN Biopsy Alone Safe in SLN Positive Breast Cancer Patients?
    van la Parra RF; de Wilt JH; Mol SJ; Mulder AH; de Roos WK; Bosscha K
    Breast J; 2015; 21(6):621-6. PubMed ID: 26391102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.